Eisai

News

Eisai has won a lawsuit blocking FDA approval of Shilpa's generic of cancer blockbuster Lenvima until 2036, although the verdict could go to appeal.

News

The EU has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, more than two years after it was filed.

News

A study has suggested early targeting of amyloid in the brains of people with inherited Alzheimer's can delay symptoms, but not all are convinced.

News

Eisai's bid to develop an integrated care platform for dementia in Japan has moved forward with the acquisition of remote monitoring firm EcoNaviSta.

News

Eisai and Biogen have another chance to convince NICE that the NHS should cover the cost of Alzheimer's therapy Leqembi.

News

Eisai and Biogen have been unable to persuade Australia's medicines regulator to approve their Alzheimer's therapy Leqembi with a narrower label.